Plain-English translation of NCT02761057 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested and compared four medications—, , , and —in people with papillary renal cell carcinoma (a type of kidney cancer that had spread or could not be surgically removed). Researchers randomly assigned participants to receive one of these medications and tracked how long it took for their cancer to grow, whether tumors shrank, how long they survived, and what side effects they experienced.
Papillary renal cell carcinoma is a rare type of kidney cancer, and doctors needed better treatment options for patients whose cancer had spread. This trial was designed to find out which of these four medications worked best and caused the fewest problems, so doctors could offer patients more effective choices.
Participants were randomly assigned to take one of the four medications by mouth, either once or twice daily for cycles of 4–6 weeks, continuing as long as their cancer did not progress and side effects remained manageable. Throughout the trial, participants had CT scans and blood tests at screening and regularly during treatment to monitor how their cancer was responding and whether the medication was causing problems. The trial involved multiple visits over several months and included bone scans if doctors suspected cancer had spread to the bones.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States